Inotuzumab ozogamicin

AMGEN PRESENTS NEW SCIENTIFIC AND CLINICAL RESEARCH ACROSS ITS DIVERSE ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2023

Retrieved on: 
Thursday, June 1, 2023
AMGN, KRAS, Amgen, KID, Osteoporosis, Research and development, Plasma, RAS, Patient, Panitumumab, Blinatumomab, Myelodysplastic syndrome, Carcinoma, CT, Bi-specific T-cell engager, Multiple myeloma, Panama, Lenalidomide, Lung cancer, MRD, Heath Robinson (codebreaking machine), Inotuzumab ozogamicin, Docetaxel, Abstract, Metastasis, RCT, Cancer, Carfilzomib, NSCLC, Denosumab, Sarcoma, Colorectal cancer, Biomarker, Busulfan, Neoplasm, Pembrolizumab, CRC, Dexamethasone, SCLC, ASCO, Talimogene laherparepvec, American Society of Clinical Oncology, ASCT, Melanoma, Annual general meeting, CDT, Melphalan, Society, Pharmaceutical industry, Medical imaging, Communications satellite, Flour, Glass wool, Vaccine, Nursing, Book, Takeda, Allotransplantation, Research

THOUSAND OAKS, Calif., June 1, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new scientific and clinical research across its diverse oncology portfolio and pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from June 2-6 in Chicago. More than 25 abstracts from Amgen-sponsored and collaborative studies, including three oral presentations and two poster discussions, will feature data in hard-to-treat tumor types, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and small cell lung cancer (SCLC).

Key Points: 
  • Additional Analyses from DeLLphi-300 Highlight Safety and Clinical Efficacy of Tarlatamab, an Investigational First-in-Class BiTE® Immunotherapy, in Patients with SCLC With Treated and Stable Brain Metastases
    THOUSAND OAKS, Calif., June 1, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new scientific and clinical research across its diverse oncology portfolio and pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from June 2-6 in Chicago.
  • More than 25 abstracts from Amgen-sponsored and collaborative studies, including three oral presentations and two poster discussions, will feature data in hard-to-treat tumor types, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and small cell lung cancer (SCLC).
  • "Our presentations at ASCO will illustrate how we're advancing novel approaches to address the toughest thoracic and colorectal cancers with limited treatment options," said David M. Reese, M.D., executive vice president of Research and Development at Amgen.
  • "We're focused on expanding the reach and impact of our transformative, first-in-class medicines to help more people living with cancer."

Triphase Accelerator Announces Positive Updated Phase 1 Data with TRPH-222 in Non-Hodgkin’s Lymphoma

Retrieved on: 
Tuesday, February 22, 2022
Trillium, Neutropenia, Hematology, Cell, Cytopenia, DLBCL, Ontario Institute for Cancer Research, Therapy, Thrombocytopenia, Acute lymphoblastic leukemia, Oncology, Incidence, Division, Partnership, Growth, Pharmacokinetics, Pfizer, Drug development, Safety, FACIT, Roswell Park Comprehensive Cancer Center, SAN, Anti-CD22 immunotoxin, NR, CEO, B-cell lymphoma, Maitansine, MCL, ORR, Patient, CRS, CD22, AES, ADC, GLOBE, CRR, Mantle cell lymphoma, NHL, B-ALL, CD19, Toxicity, Follicular lymphoma, Control, Niclas, Lymphoma, TFL, Catalent, MD, Time, Pharmaceutical industry, MaRS Discovery District, Inotuzumab ozogamicin

The observed data support further clinical studies of TRPH-222, including combinations with other anti-tumor agents in B-cell lymphoma patients.

Key Points: 
  • The observed data support further clinical studies of TRPH-222, including combinations with other anti-tumor agents in B-cell lymphoma patients.
  • The drug, formerly called CAT-02-106, was developed by Catalent Biologics using its proprietary SMARTag technology and was licensed to Triphase Accelerator.
  • Triphase Accelerator is a private drug development company with a primary focus on oncology and operations in Toronto and San Diego.
  • Triphase Accelerator was founded by the Ontario Institute for Cancer Research (OICR) and FACIT, in partnership with Toronto Innovation Acceleration Partners (TIAP) and MaRS.

Aberrant Splicing of CD22 in Acute Lymphoblastic Leukemia Underlies Resistance to Immunotherapy

Retrieved on: 
Tuesday, January 4, 2022
CHOP, RNA transfection, University, Pediatrics, Children's Hospital, Association, Lists of World Heritage Sites, Childhood leukemia, Failure, Health, Doctor of Philosophy, Patient, Pathology, Immune system, Hospital, Exon, Oncology, Cancer, RNA, Children's Hospital of Philadelphia, Science Publishing Group, American Association for Cancer Research, CD19, Disease, Observation, Lymphatic system, B-ALL, American Association, Division, Biomarker, Inotuzumab ozogamicin, Antibody, Diagnosis, Population, Leukemia, Medical laboratory, Canadian Aviation Regulations, Children's Oncology Group, DOI, Immunotherapy, CAR, Associate, Program, ALL, Alternative splicing, Philadelphia, Vaccine, Child, MD, CD22

One way to achieve this is by paying close attention to aberrant RNA splicing events, like those described in our study."

Key Points: 
  • One way to achieve this is by paying close attention to aberrant RNA splicing events, like those described in our study."
  • Adoptive immunotherapy, in which a patient's own immune system is used to kill cancer cells, has been a breakthrough in the treatment of B-ALL.
  • Although earlier studies had shown that CD22 undergoes alternative splicing, the role of these CD22 isoforms in the context of immunotherapy had not been characterized.
  • In one case, it was the only CD22 isoform, and predictably that patient did not respond to treatment with inotuzumab.

Kite's Tecartus® Demonstrates High Response Rate in Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia Earning Priority Review Designation

Retrieved on: 
Friday, June 4, 2021
Research, FDA, Hospitals, Clinical trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, Clinical medicine, Medicine, Orphan drugs, Health sciences, Breakthrough therapy, Gene therapy, Gilead Sciences, Brexucabtagene autoleucel, Inotuzumab ozogamicin, Tisagenlecleucel

In the pivotal Phase 2 portion of the trial, 71 patients with relapsed or refractory disease were enrolled.

Key Points: 
  • In the pivotal Phase 2 portion of the trial, 71 patients with relapsed or refractory disease were enrolled.
  • If approved, Tecartus would become the first and only CAR T-cell therapy approved for adults (18 years old) with relapsed or refractory ALL.
  • In 2016, Tecartus received Breakthrough Therapy Designation in recognition of the unmet medical need in adult patients with relapsed or refractory B-cell precursor ALL.
  • Tecartus has not been approved by any regulatory agency for the treatment of adult patients with relapsed or refractory ALL.

European Hematology Association: A New Anti-CD22 CAR-T Immunotherapy Saved Life of Children With Leukemia

Retrieved on: 
Saturday, June 16, 2018
Medicine, Cancer, Clinical medicine, RTT, Cancer treatments, Lymphoma, Gene therapy, Acute lymphocytic leukemia, Chimeric antigen receptor, Acute lymphoblastic leukemia, Leukemia, Inotuzumab ozogamicin

In this study, we evaluated humanized CD22-CAR-T cell therapy as a treatment option for pediatric r/r B-ALL patients who failed multiple lines of treatment including allo-HCT and CD19-CAR-T cell therapy.

Key Points: 
  • In this study, we evaluated humanized CD22-CAR-T cell therapy as a treatment option for pediatric r/r B-ALL patients who failed multiple lines of treatment including allo-HCT and CD19-CAR-T cell therapy.
  • Shanghai Yake Biotech company provided the lentiviral vector with a humanized anti-CD22 CAR design.
  • The treatment is highly effective with an overall response rate (ORR) of 86.7% and complete remission (CR) rate of 80.0%.
  • Topic: EFFICACY AND SAFETY OF CD22-DIRECTED CAR-T CELL THERAPY IN 15 PEDIATRIC REFRACTORY OR RELAPSED B ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS.